Oclacitinib: Janus Kinase Inhibitor for Canine Pruritus
Oclacitinib is a selective Janus kinase (JAK) inhibitor developed specifically for veterinary dermatology. It preferentially inhibits JAK1-dependent cytokine signaling, blocking the action of pruritogenic and pro-inflammatory cytokines including IL-31, IL-4, and IL-13, which are central mediators of allergic itch and inflammation in dogs. Oclacitinib achieves rapid itch relief, typically within 4 hours of the first dose.
Product Profile
| CAS Number | 1208319-26-9 |
|---|---|
| Molecular Formula | C15H23N5O3S |
| Appearance | White to off-white powder |
| Therapeutic Category | Veterinary antipruritic (JAK inhibitor) |
| Storage | Room temperature |
Applications
Oclacitinib maleate is approved for the control of pruritus associated with allergic dermatitis and for the control of canine atopic dermatitis in dogs at least 12 months of age. The recommended dose is 0.4–0.6 mg/kg orally twice daily for 14 days, followed by once daily for maintenance. It is not approved for use in cats. Oclacitinib has become a first-line treatment for canine allergic dermatitis alongside lokivetmab (anti-IL-31 monoclonal antibody), offering an oral alternative to long-term corticosteroid or cyclosporine therapy. The drug is formulated as flavored tablets in multiple strengths (3.6, 5.4, and 16 mg).
Why Source from TCS
TCS supplies oclacitinib to veterinary pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Oclacitinib 1208319-26-9?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Oclacitinib 1208319-26-9 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Oclacitinib 1208319-26-9?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.